<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959815</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00074818</org_study_id>
    <nct_id>NCT01959815</nct_id>
  </id_info>
  <brief_title>Novel Screening Strategies for Scleroderma PAH</brief_title>
  <official_title>Novel Screening Strategies for Scleroderma PAH (Pulmonary Arterial Hypertension)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with scleroderma can develop heart failure due to high blood pressure in the lungs&#xD;
      (a condition called pulmonary arterial hypertension). It is important to find pulmonary&#xD;
      arterial hypertension early, so that it can be treated before heart failure develops.&#xD;
      However, the tests that we now use to find the earliest form of this disease in scleroderma&#xD;
      patients are not good enough. This study will examine whether tests performed during exercise&#xD;
      can improve our ability to find early pulmonary arterial hypertension. The study will also&#xD;
      try to identify genes that are responsible for the development of pulmonary arterial&#xD;
      hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2013</start_date>
  <completion_date type="Actual">November 6, 2019</completion_date>
  <primary_completion_date type="Actual">November 6, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of pulmonary arterial hypertension</measure>
    <time_frame>Two years after enrollment.</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">156</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>Scleroderma and diagnosed PAH</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Low risk&quot; scleroderma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;High risk&quot; scleroderma</arm_group_label>
  </arm_group>
  <biospec_descr>
    <textblock>
      Blood samples will be drawn at rest and during exercise.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteers will be recruited from scleroderma clinics, pulmonary hypertension clinics, and&#xD;
        (for healthy volunteers) the Ann Arbor area.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  30 years or older;&#xD;
&#xD;
          -  diagnosis of limited or diffuse scleroderma (American College of Rheumatology&#xD;
             criteria)&#xD;
&#xD;
          -  for the &quot;high risk&quot; group, one of the following features:&#xD;
&#xD;
               -  resting transthoracic echocardiogram showing elevated right-sided pressures&#xD;
                  within previous 3 months [tricuspid regurgitation (TR) jet &gt;2.8 m/s or evidence&#xD;
                  of right ventricular dysfunction]&#xD;
&#xD;
               -  pulmonary function testing (PFT) showing abnormal diffusing capacity of carbon&#xD;
                  monoxide (DLCO) not due to significant interstitial lung disease (DLCO&lt;60%&#xD;
                  predicted or FVC: DLCO ratio &gt;1.4)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  prior diagnosis of pulmonary hypertension&#xD;
&#xD;
          -  treatment with endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or&#xD;
             prostacyclin analogues&#xD;
&#xD;
          -  previous diagnosis of obstructive lung disease or pulmonary thromboembolic disease&#xD;
&#xD;
          -  current smoker&#xD;
&#xD;
          -  significant valvular disease&#xD;
&#xD;
          -  resting echocardiogram showing left ventricular ejection fraction&lt;50% within previous&#xD;
             3 months&#xD;
&#xD;
          -  resting echocardiogram showing significant (greater than Grade I) diastolic&#xD;
             dysfunction&#xD;
&#xD;
          -  pulmonary emboli (past or present).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott H Visovatti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Scott Visovatti, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

